Lynx Biosciences™, Inc. (LynxBio®) is a clinical-stage biotechnology company combining physiologically relevant suspension cell co-culture assays, automated microfluidics, and deep learning analytics with the goal of rapidly advancing drug candidates in oncology and bringing personalized cancer treatments to patients.
®
Lorum ipsum dolar it amet
Lorum ipsum dolar it amet
Lorum ipsum dolar it amet
As a (re)mission-driven company, we leverage this clinically-proven platform to address unmet medical needs in oncology, with an initial focus on hematological malignancies. To date, we have entered into collaborations with 10+ NCI-designated cancer centers as well as Top 20 pharmaceutical companies to advance promising drug candidates and identify predictive biomarkers in clinical studies.
We are harnessing the power of our multi-omic platform to characterize complex diseases and treatments where suspension cells play critical roles, including hematological cancers, immunotherapies, and cell-based therapies.
Hematological cancers exhibit highly elaborate and heterogenous genotypic and cell signaling profiles while featuring limited actionable mutations. Additionally, the tumor microenvironment plays critical roles in the cancer cells’ behavior and response to drugs. By addressing these challenges in patient care and drug development, our approach has the unique potential [rephrase] to deliver powerful clarity of individual patients’ drug response and disease evolution.
